Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thigpen, J. T.
Right arrow Articles by Barrett, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thigpen, J. T.
Right arrow Articles by Barrett, R. J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 12, 1748-1753, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study

JT Thigpen, JA Blessing, H Ball, SJ Hummel and RJ Barrett
Department of Medicine, University of Mississippi School of Medicine, Jackson.

PURPOSE: This Gynecologic Oncology Group (GOG) trial of paclitaxel (Taxol; Bristol-Myers Squibb Co, Princeton, NJ) as salvage therapy for recurrent epithelial carcinoma of the ovary sought to confirm activity reported previously. If positive, the trial was to serve as a basis for phase III trials of Taxol in combination with platinum compounds in first-line therapy. PATIENTS AND METHODS: Patients with recurrent, persistent, or progressive ovarian carcinoma during or after platinum- based chemotherapy received Taxol 170 mg/m2 intravenously once over 24 hours every 3 weeks. All patients had measurable disease and received premedication (dexamethasone, diphenhydramine, and ranitidine) followed by Taxol. RESULTS: Of 49 patients, 45 were eligible and assessable. Among 43 patients who were assessable for response, there were eight complete and eight partial responses (37%). The median progression-free interval was 4.2 months, and median survival 16 months. Among 27 resistant patients who progressed during or within 6 months of prior platinum-based therapy or had stable disease as the best response, five complete (18%) and four partial (15%) responses were observed (33%). The median progression-free interval was 4 months. Among 16 sensitive patients who responded and progressed more than 6 months after prior platinum-based treatment, three complete (19%) and four partial (25%) responses were observed (44%). The median progression-free interval was 4.9 months. Grade 4 neutropenia (< 500/microL), the most frequent and severe toxicity, occurred in 73% of patients. Other hematologic effects were less frequent and less severe. Cardiac problems and hypersensitivity reactions were observed in one patient each. CONCLUSION: Taxol is a highly active agent in ovarian carcinoma, even in patients who are clinically resistant to platinum-based chemotherapy, and produces frequent and severe, albeit manageable, myelosuppression. It is clearly active as salvage therapy for ovarian carcinoma.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
Y. ITANI, K. HOSOKAWA, K. ITO, S. TAKEUCHI, T. TABATA, H. TSUBAMOTO, H. FUJITA, M. AKIYAMA, and S. ADACHI
A Phase I/II Study of Docetaxel and Gemcitabine Combination for Chemotherapy-resistant Ovarian Cancer
Anticancer Res, May 1, 2009; 29(5): 1521 - 1526.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann
Current Management Strategies for Ovarian Cancer
Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Markman
New, Expanded, and Modified Use of Approved Antineoplastic Agents in Ovarian Cancer
Oncologist, February 1, 2007; 12(2): 186 - 190.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
M. Markman
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Arch Intern Med, July 24, 2006; 166(14): 1446 - 1448.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. S. Huang, L. Lopez-Barcons, B. S. Freeze, A. B. Smith III, G. L. Goldberg, S. B. Horwitz, and H. M. McDaid
Potentiation of Taxol Efficacy by Discodermolide in Ovarian Carcinoma Xenograft-Bearing Mice
Clin. Cancer Res., January 1, 2006; 12(1): 298 - 304.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. R. Garrett, M. N. Fishman, R. R. Rago, C. C. Williams, A. M. Dellaportas, J. J. Mahany, R. M. Lush, W. S. Dalton, A. Gollerkeri, M. B. Cohen, et al.
Phase I Study of a Novel Taxane BMS-188797 in Adult Patients with Solid Malignancies
Clin. Cancer Res., May 1, 2005; 11(9): 3335 - 3341.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Sabbatini, C. Aghajanian, D. Dizon, S. Anderson, J. Dupont, J. V. Brown, W. A. Peters, A. Jacobs, A. Mehdi, S. Rivkin, et al.
Phase II Study of CT-2103 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
J. Clin. Oncol., November 15, 2004; 22(22): 4523 - 4531.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. S. Rustin, R. C. Bast Jr., G. J. Kelloff, J. C. Barrett, S. K. Carter, P. D. Nisen, C. C. Sigman, D. R. Parkinson, and R. W. Ruddon
Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer
Clin. Cancer Res., June 1, 2004; 10(11): 3919 - 3926.
[Full Text] [PDF]

Home page
 JCOHome page
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol., May 15, 2003; 21(90100): 149s - 167.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. C. Bodurka, C. Levenback, J. K. Wolf, J. Gano, J. T. Wharton, J. J. Kavanagh, and D. M. Gershenson
Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer
J. Clin. Oncol., January 15, 2003; 21(2): 291 - 297.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Markman, J. Hall, D. Spitz, S. Weiner, L. Carson, L. Van Le, and M. Baker
Phase II Trial of Weekly Single-Agent Paclitaxel in Platinum/Paclitaxel-Refractory Ovarian Cancer
J. Clin. Oncol., May 1, 2002; 20(9): 2365 - 2369.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
Is There a "Best" Choice of Second-Line Agent in the Treatment of Recurrent, Potentially Platinum-Sensitive Ovarian Cancer?
J. Clin. Oncol., March 1, 2002; 20(5): 1158 - 1160.
[Full Text] [PDF]

Home page
 JCOHome page
R. F. Ozols
Recurrent Ovarian Cancer: Evidence-Based Treatment
J. Clin. Oncol., March 1, 2002; 20(5): 1161 - 1163.
[Full Text] [PDF]

Home page
 JCOHome page
M. G. Cantu, A. Buda, G. Parma, R. Rossi, I. Floriani, C. Bonazzi, T. Dell'Anna, V. Torri, and N. Colombo
Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens
J. Clin. Oncol., March 1, 2002; 20(5): 1232 - 1237.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. Hummer, E. Venkatraman, and D. R. Spriggs
Retrospective Analysis of Carboplatin and Paclitaxel as Initial Second-Line Therapy for Recurrent Epithelial Ovarian Carcinoma: Application Toward a Dynamic Disease State Model of Ovarian Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1238 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Ota, T. Sugiyama, K. Komai, N. Hirai, S. Kumagai, K. Ushijima, T. Nishida, and T. Kamura
Weekly 1 Hour Paclitaxel Infusion in Patients with Recurrent Gynecological Tumors: a Pilot Study
Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 395 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. C. Kohn, E. Reed, G. A. Sarosy, L. Minasian, K. S. Bauer, F. Bostick-Bruton, V. Kulpa, E. Fuse, A. Tompkins, M. Noone, et al.
A Phase I Trial of Carboxyamido-triazole and Paclitaxel for Relapsed Solid Tumors: Potential Efficacy of the Combination and Demonstration of Pharmacokinetic Interaction
Clin. Cancer Res., June 1, 2001; 7(6): 1600 - 1609.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Gore, W. ten Bokkel Huinink, J. Carmichael, A. Gordon, N. Davidson, R. Coleman, M. Spaczynski, J.-F. Heron, G. Bolis, H. Malmstrom, et al.
Clinical Evidence for Topotecan-Paclitaxel Non-Cross-Resistance in Ovarian Cancer
J. Clin. Oncol., April 1, 2001; 19(7): 1893 - 1900.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. A. Malik
Altretamine is an Effective Palliative Therapy of Patients with Recurrent Epithelial Ovarian Cancer
Jpn. J. Clin. Oncol., February 1, 2001; 31(2): 69 - 73.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
P. J. Stiff, J. Veum-Stone, H. M. Lazarus, L. Ayash, J. R. Edwards, A. Keating, J. P. Klein, D. J. Oblon, T. C. Shea, S. Thome, et al.
High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report
Ann Intern Med, October 3, 2000; 133(7): 504 - 515.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Piccart, J. A. Green, A. J. Lacave, N. Reed, I. Vergote, P. Benedetti-Panici, A. Bonetti, V. Kristeller-Tome, C. M. Fernandez, D. Curran, et al.
Oxaliplatin or Paclitaxel in Patients With Platinum-Pretreated Advanced Ovarian Cancer: A Randomized Phase II Study of the European Organization for Research and Treatment of Cancer Gynecology Group
J. Clin. Oncol., March 13, 2000; 18(6): 1193 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. P. McGuire, J. A. Blessing, M. A. Bookman, S. S. Lentz, and C. J. Dunton
Topotecan Has Substantial Antitumor Activity as First-Line Salvage Therapy in Platinum-Sensitive Epithelial Ovarian Carcinoma: A Gynecologic Oncology Group Study
J. Clin. Oncol., March 1, 2000; 18(5): 1062 - 1062.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Markman and M. A. Bookman
Second-Line Treatment of Ovarian Cancer
Oncologist, February 1, 2000; 5(1): 26 - 35.
[Abstract] [Full Text]

Home page
 JCOHome page
F. M. Muggia, P. S. Braly, M. F. Brady, G. Sutton, T. H. Niemann, S. L. Lentz, R. D. Alvarez, P. R. Kucera, and J. M. Small
Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
J. Clin. Oncol., January 5, 2000; 18(1): 106 - 106.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Groopman and L. M. Itri
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
J Natl Cancer Inst, October 6, 1999; 91(19): 1616 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Vasey, J. Paul, A. Birt, E. J. Junor, N. S. Reed, R. P. Symonds, R. Atkinson, J. Graham, S. M. Crawford, R. Coleman, et al.
Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer
J. Clin. Oncol., July 1, 1999; 17(7): 2069 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. L. Judson, J. M. Watson, P. A. Gehrig, W. C. Fowler Jr., and J. S. Haskill
Cisplatin Inhibits Paclitaxel-induced Apoptosis in Cisplatin-resistant Ovarian Cancer Cell Lines: Possible Explanation for Failure ofCombination Therapy
Cancer Res., May 1, 1999; 59(10): 2425 - 2432.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. Makatsoris and M. V. Seiden
High-Dose Therapy for Ovarian Carcinoma
Oncologist, October 1, 1997; 2(5): 330 - 339.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Paclitaxel and {blacktriangledown}docetaxel in breast and ovarian cancer
DTB, June 1, 1997; 35(6): 43 - 46.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. P. McGuire, W. J. Hoskins, M. F. Brady, P. R. Kucera, E. E. Partridge, K. Y. Look, D. L. Clarke-Pearson, and M. Davidson
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
N. Engl. J. Med., January 4, 1996; 334(1): 1 - 6.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. K. Rowinsky and R. C. Donehower
Paclitaxel (Taxol)
N. Engl. J. Med., April 13, 1995; 332(15): 1004 - 1014.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1994 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online